Chemical Properties:
Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Palbociclib Related Intermediates: Palbociclib CAS 571190-30-2 5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5 5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8 tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7 tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4| Item | Specifications |
| Appearance | Colorless to Light Yellow Liquid |
| Purity / Analysis Method | >99.0% (GC) |
| Melting Point | 29.0~30.0℃ |
| Water (by Karl Fischer) | <0.50% |
| 2,4-Dichloropyrimidine | <0.50% (GC) |
| Maximun Single Impurity | <0.50% (GC) |
| Total Impurities | <1.00% |
| 1 H NMR Spectrum | Consistent With Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Palbociclib (CAS: 571190-30-2) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 5-Bromo-2,4-Dichloropyrimidine |
| CAS Number | 36082-50-5 |
| CAT Number | RF-PI1852 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C4HBrCl2N2 |
| Molecular Weight | 227.87 |
| Boiling Point | 128℃/15 mmHg (lit.) |
| Density | 1.781 g/mL at 25℃ (lit.) |
| Refractive Index | n20/D 1.603 (lit.) |
| Solubility | Soluble in Methanol |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
5-Bromo-2,4-Dichloropyrimidine (CAS: 36082-50-5) may be employed as starting reagent for the synthesis of positive allosteric modulators for GABAB receptors (drug-like class of compounds) and pyridinepyrimidine analogs. 5-Bromo-2,4-Dichloropyrimidine can be used as an intermediate of Palbociclib (CAS: 571190-30-2). Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
